In vitro and in vivo preclinical studies comparing the SSTR2-antagonist 177Lu-OPS201 (also referred to as 177Lu-DOTA-JR11, 177Lu-IPN01072 or 177Lu-satoreotide tetraxetan) to 177Lu-DOTATATE, have shown that 177Lu-OPS201 exhibits a higher tumor uptake, higher number of double-strand breaks, longer tumor residence time and improved tumor-to-kidney dose ratio [139,140]. This evidence concerns the gene SSTR2 and neoplasm.